Brokerages from Wall Street expect MacroGenics, Incorporated (NASDAQ: MGNX) shall soon post their EPS for the fiscal quarter at -$0.53. The highest among the four estimates is $0.91 while the lowest is at $0.16. This is a sign of a 41.8% growth rate for year-after-year.
Details Of MGNX Stock
$1.43 is expected as the earnings for the full-year this year with the EPS estimated to be between $2 and $1.12. Analysts anticipate will post an EPS worth $1.98 for next year.
Quite a few researchers have picked up MGNX recently. Barclays updated their rating of the stock to “overweight”, setting an objective price of $40 on 18th March. HC Wainwright maintained their “buy” rating setting a target price of $36 on 22nd December. Lastly, Morgan Stanley gave a rating of “underweight” on 4th March and set the target price as $15. In general, MGNX has a “buy” rating with a general objective price set at $32.18.
The stock reached $33.20 on Friday with 717,971 of the stock being traded. 839,076 is the average trade volume. The stock’s lowest price in a year is $5 while the highest has been $33.25. The moving average for fifty-days stands at $24.99 while for two-hundred days it stands at $23.72.
James Karrels, the CFO, recently sold 15000 of the company’s stock at the average value of $33, with a total selling price of $495000. Ezio Bonvini, the SVP, also sold 3917 shares at the average value of $32. Federated Hermes Inc., Marshall Wace North America L. P., Pacer Advisors Inc., and Penserra Capital Management all grew their holdings in MGNX.
The company deals in the industry of biopharmaceuticals. The firm researches and develops therapeutics that are based on antibodies specifically for cancer in the US. Its products include Magetuximab, a hopefully effective drug against gastroesophageal and breast cancers.
